HC Wainwright Has Negative Forecast for MLTX Q3 Earnings

Key Points

• HC Wainwright revised its Q3 2025 EPS estimate for MoonLake Immunotherapeutics downward to ($0.96), reflecting a decrease from a prior estimate of ($0.79), alongside a full-year projection of ($1.79) EPS.
• The company recently reported Q2 earnings of ($0.87) EPS, missing estimates by $0.14 and showing a decline from ($0.39) EPS in the same quarter last year.
• Despite negative earnings forecasts, various analysts hold a consensus rating of "Moderate Buy," with an average price target of $74.43 for the stock.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities researchers at HC Wainwright dropped their Q3 2025 EPS estimates for MoonLake Immunotherapeutics in a note issued to investors on Monday, August 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.96) for the quarter, down from their previous estimate of ($0.79). The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($1.02) EPS and FY2026 earnings at ($3.64) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period in the prior year, the business posted ($0.39) EPS.

A number of other analysts have also recently weighed in on MLTX. Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target for the company in a research report on Monday, May 19th. Redburn Atlantic upgraded MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Rothschild & Co Redburn initiated coverage on shares of MoonLake Immunotherapeutics in a research note on Monday, July 28th. They issued a "neutral" rating and a $65.00 price objective for the company. Royal Bank Of Canada reiterated an "outperform" rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $74.43.

MoonLake Immunotherapeutics Trading Up 1.5%

Shares of NASDAQ:MLTX opened at $55.65 on Thursday. The company has a current ratio of 16.65, a quick ratio of 16.65 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $3.56 billion, a PE ratio of -20.02 and a beta of 1.27. MoonLake Immunotherapeutics has a 1 year low of $31.42 and a 1 year high of $58.26. The firm has a fifty day moving average price of $49.33 and a 200 day moving average price of $43.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in MoonLake Immunotherapeutics by 17.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company's stock valued at $2,287,000 after acquiring an additional 6,422 shares during the period. Victory Capital Management Inc. grew its holdings in shares of MoonLake Immunotherapeutics by 44.6% during the 1st quarter. Victory Capital Management Inc. now owns 258,150 shares of the company's stock worth $10,086,000 after purchasing an additional 79,649 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of MoonLake Immunotherapeutics during the 1st quarter worth approximately $273,000. Rice Hall James & Associates LLC increased its position in shares of MoonLake Immunotherapeutics by 23.7% during the first quarter. Rice Hall James & Associates LLC now owns 137,516 shares of the company's stock valued at $5,373,000 after purchasing an additional 26,383 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at $3,485,000. Institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.